Remus Pharmaceuticals's Days Sales Outstanding for the
six
months ended in Mar. 2026 was 57.86.
Remus Pharmaceuticals's Days Inventory for the
six
months ended in Mar. 2026 was 41.27.
Remus Pharmaceuticals's Days Payable for the
six
months ended in Mar. 2026 was 46.73.
Therefore, Remus Pharmaceuticals's Cash Conversion Cycle (CCC) for the
six
months ended in Mar. 2026 was 52.40.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Remus Pharmaceuticals Cash Conversion Cycle Related Terms
Remus Pharmaceuticals Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Remus Pharmaceuticals's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:REMUS vs MCK, CAH, COR: Cash Conversion Cycle Comparison
For the Medical Distribution subindustry, Remus Pharmaceuticals's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals Cash Conversion Cycle vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Remus Pharmaceuticals's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Remus Pharmaceuticals (NSE:REMUS) has a Cash Conversion Cycle of 52.40 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Remus Pharmaceuticals and its competitors.
Is Remus Pharmaceuticals' Cash Conversion Cycle too high?
Remus Pharmaceuticals' current Cash Conversion Cycle is 52.40. The Medical Distribution industry median Cash Conversion Cycle is 55.95. Remus Pharmaceuticals' value of 52.40 is 6.3% below this industry median. Overall, Remus Pharmaceuticals has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Cash Conversion Cycle compare to MCK and CAH?
Remus Pharmaceuticals' Cash Conversion Cycle of 52.40 can be compared against companies in the Medical Distribution industry. The industry median Cash Conversion Cycle is 55.95. Remus Pharmaceuticals' value of 52.40 is 6.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Distribution company?
The median Cash Conversion Cycle among Medical Distribution companies is 55.95, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Remus Pharmaceuticals's current Cash Conversion Cycle of 52.40 is 6.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median Cash Conversion Cycle is 55.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current Cash Conversion Cycle is 52.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹767.40 — trading 63% below its estimated fair value. The current Cash Conversion Cycle is 52.40 and 6.3% below the Medical Distribution industry median of 55.95. Remus Pharmaceuticals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Cash Conversion Cycle is 52.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹767.40 is trading 63% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
Cash Conversion Cycle: 52.40
GF Value™: ₹2,071.36 vs. price of ₹767.40 (63% below fair value)
Industry Position: 6.3% below the Medical Distribution median
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
54GF Score
Get the complete analysis for NSE:REMUS
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
